Institut Regional Du Cancer De Montpellier

The medical center is at the forefront of research in Non-Small Cell Lung Cancer (NSCLC), focusing on advanced therapeutic strategies for patients who have progressed after initial treatments. The center's work includes exploring novel drug combinations and targeted therapies to improve progression-free survival.

• Dato-DXd monotherapy and combination therapies
• Osimertinib and chemotherapy combinations
• Patritumab Deruxtecan versus platinum-based chemotherapy

These studies aim to enhance treatment efficacy and patient outcomes by integrating cutting-edge research with clinical applications.

Specializing in Urothelial Cancer, the center conducts pivotal trials to assess the effectiveness of innovative treatments like sacituzumab govitecan. The focus is on improving overall survival rates and offering new hope to patients with metastatic or locally advanced conditions.

• Sacituzumab Govitecan versus physician's choice treatments
• Immunotherapy combinations for untreated advanced cases

These efforts are crucial in developing more effective therapeutic options and enhancing the quality of life for patients.

The center is a leader in Breast Cancer research, particularly in metastatic cases with specific receptor profiles. By investigating the impact of advanced imaging techniques and combination therapies, the center aims to refine treatment strategies and improve patient management.

• 18F-FES PET/CT in ER-positive, HER2-negative cases
• Durvalumab, olaparib, and fulvestrant combinations
• Trastuzumab deruxtecan versus T-DM1

These studies are pivotal in advancing personalized medicine approaches and optimizing therapeutic outcomes.

Focusing on Colorectal Cancer, the center is engaged in trials that explore innovative treatment combinations to enhance survival rates in metastatic cases. The research includes evaluating systemic therapies and novel drug regimens.

• Petosemtamab in advanced solid tumors
• Regorafenib and irinotecan combinations
• EO4010 cancer vaccine therapy

These initiatives are designed to push the boundaries of current treatment paradigms and offer new hope to patients.

The center's research in Prostate Cancer focuses on castration-resistant and hormone-sensitive forms, aiming to improve survival outcomes through innovative drug combinations and targeted therapies.

• Acetylsalicylic acid and atorvastatin in castration-resistant cases
• Enzalutamide and Ra223 combinations
• Capivasertib and abiraterone for PTEN-deficient cases

These studies are crucial in developing more effective treatment regimens and enhancing patient quality of life.

In the field of Ovarian Cancer, the center is pioneering research into advanced therapeutic options for recurrent and high-grade cases. The focus is on improving progression-free survival and overall treatment efficacy.

• ADP A2M4CD8 and nivolumab combinations
• Raludotatug Deruxtecan for platinum-resistant cases
• Avutometinib and defactinib combinations

These efforts are aimed at providing new therapeutic avenues and improving patient outcomes in challenging cases.